Steve Harr
CIK 1627387 · President & CEO · last filed 2026-03-10
Steve Harr is a President & CEO who has filed 28 SEC Form 4 insider transactions across 3 companies since 2015. The most recent filing, for SANA, was dated Mar 10, 2026. Across all open-market trades the lifetime net is −$5.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $21.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$21.77M
3
28
-$5.19M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SANA | President & CEO | 8,124,070 | $2.68 | $21.77M | $0 | 8 | 2026-03-10 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | — | — | — | $0 | 4 | 2019-02-15 |
| Juno Therapeutics, Inc. (JUNO) Delisted | CFO & Head, Corp. Development | 97,152 | — | — | -$5.19M | 16 | 2018-03-07 |
Recent Filings
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-10 | SANA | Mixed | +67,321 | -$75.8K | EDGAR |
| 2026-03-06 | SANA | Grant (A) | — | $0 | EDGAR |
| 2025-03-10 | SANA | Mixed | +37,180 | -$32.8K | EDGAR |
| 2024-03-08 | SANA | Grant (A) | — | $0 | EDGAR |
| 2023-03-03 | SANA | Grant (A) | — | $0 | EDGAR |
| 2022-04-15 | SANA | Gift (G) | −334,000 | $0 | EDGAR |
| 2022-03-08 | SANA | Grant (A) | — | $0 | EDGAR |
| 2021-02-10 | SANA | Conv (C) | +2,031,250 | $0 | EDGAR |
| 2019-02-15 | Loxo Oncology, Inc. (LOXO) Delisted | Disp (D) | — | $0 | EDGAR |
| 2018-06-14 | Loxo Oncology, Inc. (LOXO) Delisted | Grant (A) | — | $0 | EDGAR |